Study shows potential of new monoclonal antibody in treating COVID-19
LOS ANGELES, March 7 (Xinhua) -- A new study shows that a new monoclonal antibody is promising in treating COVID-19.
In a randomized trial of Foralumab, a humanized monoclonal antibody against the immune protein CD3, researchers nasally administered 100 mg of Foralumab each day for 10 days to 12 outpatients with mild to moderate COVID-19, according to the study published Tuesday on the Proceedings of the National Academy of Sciences.
Patients who received the treatment exhibited reduced lung inflammation compared with patients who did not receive the antibody.
Additionally, Foralumab modulated genes involved in regulating the inflammatory T cell response, and similar genetic modulation was observed in patients with multiple sclerosis who received Foralumab, according to the study.
The results suggest that the monoclonal antibody might hold therapeutic potential for multiple human inflammatory diseases, according to the study.
Photos
Related Stories
- China shared data, research on COVID-19 origin: foreign ministry
- Three years of resilience of the Chinese people
- Omicron subvariant XBB.1.5 accounts for nearly 90 pct new COVID-19 cases in U.S.
- ECDC de-escalates 3 COVID-19 lineages from variants of concern list
- UK's ethnic minorities more likely to die from COVID-19: The Guardian
Copyright © 2023 People's Daily Online. All Rights Reserved.